Streetbeat News

SHWZ

Medicine Man Technologies Inc

Employees

258

Industry

Administrative Management and General Management Consulting Services

Open

0.00

Mkt cap

1.6M

Volume

High

0.02

P/E Ratio

-0.02

52-wk high

1.04

Low

0.00

Div yield

N/A

52-wk low

0.00

C21 Investments Inc. has acquired a 6,500-square-foot cannabis dispensary in South Reno, Nevada, for $3.5 million. The store will be rebranded under Silver State Relief. Additionally, Higher Collective opened a new dispensary in Torrington, Connecticut, and From the Earth launched a new store in Kansas City, Missouri. Medicine Man Technologies, operating as Schwazze, opened its 35th New Mexico dispensary.

Portfolio Pulse from Jelena Martinovic

June 11, 2024 | 12:47 am

Benchmark analyst Mike Hickey has reiterated a Buy rating on Medicine Man Technologies (OTC:SHWZ) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 2:00 pm

Schwazze (OTC:SHWZ) reported its Q1 2024 financial results, showing a 9% increase in overall cannabis sales despite a 10% decline in Colorado sales. The company faced competitive challenges but focused on enhancing retail and wholesale strategies. Key financial metrics include a total revenue of $41.6 million, a net loss of $16.1 million, and a decrease in cash and cash equivalents to $13.2 million. Schwazze continues to expand its retail footprint and improve product performance.

Portfolio Pulse from Nicolás Jose Rodriguez

May 15, 2024 | 10:14 pm

Medicine Man Technologies (OTC:SHWZ) reported a Q1 2024 GAAP EPS of $(0.24), missing the $(0.16) estimate by 50%. However, sales of $41.601M beat the $39.834M estimate, marking a 4.44% increase.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 8:12 pm

The cannabis industry is witnessing significant executive changes across various companies, with new CEOs, CFOs, COOs, and board members being appointed. These changes come as the industry prepares for the Benzinga Cannabis Capital Conference in Florida, highlighting the sector's dynamic nature and growth. Notably, U.S.-based cannabis executives' salaries have surpassed the $500,000 mark, indicating the industry's lucrative potential. Companies like Decibel Cannabis, Schwazze, DIZPOT, and others have announced leadership changes, aiming to strengthen their market positions and expand operations.

Portfolio Pulse from Jelena Martinovic

April 16, 2024 | 12:22 am

The Viridian Cannabis Deal Tracker reports a 39% increase in market value for major cannabis companies, with valuation multiples rising for 11 out of 14 major multi-state operators (MSOs). This growth is attributed to investors betting on long-term growth over short-term earnings, with companies like Curaleaf (CURLF) and Schwazze (SHWZ) experiencing valuation increases despite flat or declining EBITDA. GTI (GTBIF) and Cresco (CRLBF) also saw increases in both EBITDA multiples and estimates, indicating strong fundamentals. The anticipation of cannabis rescheduling is driving multiple expansions, with a focus on EBITDA growth as a key indicator of corporate health.

Portfolio Pulse from Nicolás Jose Rodriguez

April 15, 2024 | 11:53 pm

Viridian Capital Advisors' analysis reveals a 292% surge in trading volume for the cannabis sector, with AYR Wellness leading. Despite this, major Multi-State Operators like Curaleaf and AYR face liquidity challenges, with increased days required to trade their market cap. The report emphasizes the importance of liquidity for investors and hints at potential DEA rescheduling as a factor for market outlook but notes skepticism about attracting more institutional investment without further reforms.

Portfolio Pulse from Nicolás Jose Rodriguez

April 11, 2024 | 5:17 pm

Schwazze (OTC:SHWZ) reported a revenue increase of 8% in Q4 2023 to $43.3 million, despite a challenging competitive landscape in the cannabis retail sector, particularly in Colorado and New Mexico. The company expanded its store footprint by over 50% to 63 dispensaries. However, gross profit dropped significantly to $7.0 million from $21.7 million in the same quarter last year, leading to a net loss of $33.9 million. The company attributes the fierce competition and market pressures for the financial outcomes but remains optimistic about future growth and regulatory momentum.

Portfolio Pulse from Maureen Meehan

March 28, 2024 | 3:42 pm

Benchmark analyst Mike Hickey maintains a Buy rating on Medicine Man Technologies (OTC:SHWZ) but lowers the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 3:15 pm

Medicine Man Technologies (OTC:SHWZ) reported Q4 earnings with an EPS of $-0.38, missing estimates by -192.0% against an expected $-0.13. Revenue increased by $3.18 million from the previous year. The company's past earnings performance shows a mixed trend with a notable 8.0% drop in share price following the last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.